One year in review
One year in review 2019: systemic lupus erythematosus
D. Zucchi1, E. Elefante2, E. Calabresi3, V. Signorini4, A. Bortoluzzi5, C. Tani6
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy. dinazucchi@hotmail.it
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, and Department of Medical Biotechnologies, University of Siena, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
- Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna, Ferrara, Italy.
- Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
CER12520
2019 Vol.37, N°5
PI 0715, PF 0722
One year in review
Free to view
(click on article PDF icon to read the article)
PMID: 31376267 [PubMed]
Received: 19/06/2019
Accepted : 01/07/2019
In Press: 19/07/2019
Published: 29/08/2019
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune connective-tissue disorder with a wide range of clinical manifestations that predominantly affect women. Many aspects of its pathogenesis are still unclear, and new therapeutic strategies are progressively emerging. Thus, in this review we aim to summarise the most relevant data on SLE that emerged during 2018, following the previous annual review of this series. In particular, the review will focus on new insights in SLE regarding new pathogenetic pathways, new biomarkers, new data on clinical manifestations, clinical outcomes and comorbidities and what has emerged on new drugs and new therapeutic strategies.
